#AS­CO18: Bris­tol-My­ers takes an­oth­er stab at a pos­i­tive im­pres­sion for Check­Mate-227

CHICA­GO — Af­ter get­ting snubbed at AACR in its show­down with Mer­ck over front­line lung can­cer, Bris­tol-My­ers Squibb is back at AS­CO with up­dat­ed da­ta on its check­point star Op­di­vo in com­bi­na­tion with chemo as well as a low dose of the CT­LA-4 drug Yer­voy. And it’s like­ly to still face an up­hill climb against the skep­tics.

That check­point plus chemo com­bo — where Mer­ck has been reign­ing supreme — came in with a haz­ard ra­tio of 0.74 among pa­tients with less than 1% PD-L1 ex­pres­sion. And the Op­di­vo/Yer­voy com­bo did bet­ter on pro­gres­sion-free sur­vival at this stage of the 1b por­tion of Check­Mate-227 when pa­tients are win­nowed down by the size of their tu­mor mu­ta­tion bur­den.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.